Skip to main content
. 2017 Dec 27;57(10):1345–1353. doi: 10.2169/internalmedicine.9826-17

Figure 2.

Figure 2.

The cumulative progression-free survival of patients with extrahepatic lesions or macrovascular invasion treated with a combination of radiotherapy and sorafenib therapy (group RS, n=15) and those treated with sorafenib monotherapy (group S, n=47). The numbers below the X-axis indicate the number of patients at risk.